No Data
No Data
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
Medicenna Reports MDNA11's Compelling Anti-Cancer Activity Is Associated With Significant Expansion of 'Stem-Like' Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update
Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones
Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025
Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)
H.C. Wainwright Maintains Medicenna Therapeutics(MDNAF.US) With Buy Rating, Maintains Target Price $2.5
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.
Rana Hasan1 : List too long